National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 69035-69036 [2022-25018]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 221 / Thursday, November 17, 2022 / Notices
and first episode psychosis,’’ submitted
to NIMH, NIH, on February 2, 2018.
Specifically, ORI finds that
Respondent knowingly, intentionally, or
recklessly falsified the Positron
Emission Tomography (PET) data of the
binding of radiopharmaceutical
[11C]NOP–1A (NOP) in brain regions
between the patient group and healthy
volunteer (HV) group. Respondent
selectively included one (1) and
excluded three (3) participants with
their PET data in the HV group and
selectively excluded four (4)
participants with their PET data in the
patient group, to falsely state that the
NOP binding in the patient group was
statistically higher than that in the HV
group in Figure 3, right panel, and the
corresponding text in grant application
R01 MH118495–01.
Dr. Mizrahi entered into a Voluntary
Settlement Agreement (Agreement) and
voluntarily agreed to the following:
(1) Respondent will have her research
supervised for a period of one (1) year
beginning on November 3, 2022 (the
‘‘Supervision Period’’). Prior to the
submission of an application for PHS
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of one (1) year
from the effective date of the
Agreement. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
discussion with Respondent of the
VerDate Sep<11>2014
17:26 Nov 16, 2022
Jkt 259001
primary data represented in those
documents and will include a
certification to ORI that the data
presented in the proposed application,
report, manuscript, or abstract are
supported by the research record.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing her submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that her
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that she has not
participated in any capacity in PHSsupported research.
(5) During the Supervision Period,
Respondent will exclude herself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
Dated: November 14, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–25031 Filed 11–16–22; 8:45 am]
BILLING CODE 4150–31–P
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
Frm 00040
Fmt 4703
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR22–171: NIDDK
Central Repository Non-Renewable Sample
Access (X01) Review.
Date: December 15, 2022.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of Diabetes and Digestive
and Kidney Diseases, 2 Democracy, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Najma S. Begum, Ph.D.,
Scientific Review Officer Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Information is also available on the
Institute’s/Center’s home page:
www.niddk.nih.gov/, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: November 14, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–25023 Filed 11–16–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
69035
Sfmt 4703
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
E:\FR\FM\17NON1.SGM
17NON1
69036
Federal Register / Vol. 87, No. 221 / Thursday, November 17, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Emphasis Panel; AMP–PD Extracellular RNA
Sequencing Research Resource Review (R24).
Date: December 9, 2022.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Mir Ahamed Hossain,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive
Blvd., Suite 3208, MSC 9529, Bethesda, MD
20892–9529, 301–496–9223,
mirahamed.hossain@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Clinical Trials and
Biomarker Studies in Stroke.
Date: December 12, 2022.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892–
9529, 301–435–6033, rajarams@mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Clinical Trial Readiness for
Rare Neurological and Neuromuscular
Diseases.
Date: December 12, 2022.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Ana Olariu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892–
9529, 301–496–9223, Ana.Olariu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS.)
Dated: November 10, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Submission for OMB Review; 30-Day
Comment Request Application and
Impact of Clinical Research Training
on Healthcare Professionals in
Academia and Clinical Research
(Office of the Director)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Resource Related
Research Projects (R24 Clinical Trial Not
Allowed).
Date: December 12, 2022.
Time: 9:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G11A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: J. Bruce Sundstrom, Ph.D.
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G11A Rockville, MD
20852 240–669–5045 sundstromj@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 10, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–25022 Filed 11–16–22; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2022–25018 Filed 11–16–22; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:26 Nov 16, 2022
Jkt 259001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Anne Zajicek,
Deputy Director, Office of Clinical
Research, OD, NIH, Building 1, Room
208A, 1 Center Drive, Bethesda, MD
20892, or call non-toll-free number (301)
480–9913 or Email your request,
including your address to: zajiceka@
mail.nih.gov.
ADDRESSES:
This
proposed information collection was
previously published in the Federal
Register on Tuesday, August 30, 2022,
Volume 87, pages 52979–52980 (87 FR
52979) and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The Office of Clinical
Research, Office of the Director,
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\17NON1.SGM
17NON1
]]>Agencies
[Federal Register Volume 87, Number 221 (Thursday, November 17, 2022)]
[Notices]
[Pages 69035-69036]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-25018]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special
[[Page 69036]]
Emphasis Panel; AMP-PD Extracellular RNA Sequencing Research
Resource Review (R24).
Date: December 9, 2022.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Mir Ahamed Hossain, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC
9529, Bethesda, MD 20892-9529, 301-496-9223,
[email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Clinical Trials and Biomarker
Studies in Stroke.
Date: December 12, 2022.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Shanta Rajaram, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC
9529, Bethesda, MD 20892-9529, 301-435-6033, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Clinical Trial Readiness for Rare
Neurological and Neuromuscular Diseases.
Date: December 12, 2022.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Ana Olariu, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Activities, NINDS/
NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD
20892-9529, 301-496-9223, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS.)
Dated: November 10, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy, Office of
Federal Advisory Committee Policy.
[FR Doc. 2022-25018 Filed 11-16-22; 8:45 am]
BILLING CODE 4140-01-P
